Waymo Unveils New Robotaxi with Zeekr, Seeks Over $10 Billion Funding
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Source: Benzinga
- New Robotaxi Launch: Waymo unveiled its new Robotaxi, named Ojai, in collaboration with Zeekr at the 2026 Consumer Electronics Show, integrating next-generation technology and undergoing testing in Arizona, which signifies the company's ongoing innovation in the autonomous taxi sector.
- International Expansion Plans: Waymo is looking to expand its services into London, working with local partner Moove and seeking regulatory approvals to operate Robotaxis, demonstrating its ambition for global market penetration.
- Significant Funding Target: The company is reportedly seeking over $10 billion in funding at a valuation exceeding $100 billion, which will provide substantial financial backing for its technology development and market expansion, further solidifying its leading position in the U.S. Robotaxi market.
- Strong Market Performance: Waymo completed over 14 million paid Robotaxi rides last year, showcasing robust market performance and customer demand, which enhances its competitive edge in the autonomous driving industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOOGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOOGL
Wall Street analysts forecast GOOGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOOGL is 338.25 USD with a low forecast of 279.00 USD and a high forecast of 390.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
34 Analyst Rating
27 Buy
7 Hold
0 Sell
Strong Buy
Current: 338.250
Low
279.00
Averages
338.25
High
390.00
Current: 338.250
Low
279.00
Averages
338.25
High
390.00
About GOOGL
Alphabet Inc. is a holding company. The Company's segments include Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment includes infrastructure and platform services, collaboration tools, and other services for enterprise customers. Its Other Bets segment is engaged in the sale of healthcare-related services and Internet services. Its Google Cloud provides enterprise-ready cloud services, including Google Cloud Platform and Google Workspace. Google Cloud Platform provides access to solutions such as artificial intelligence (AI) offerings, including its AI infrastructure, Vertex AI platform, and Gemini for Google Cloud; cybersecurity, and data and analytics. Google Workspace includes cloud-based communication and collaboration tools for enterprises, such as Calendar, Gmail, Docs, Drive, and Meet.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rhythm Pharmaceuticals: A Hidden Growth Stock Soaring
- Significant Market Potential: Rhythm Pharmaceuticals has a market cap of $6.8 billion, and despite its relatively small size, its stock has outperformed both Alphabet and Nvidia over the past 12 months, indicating strong market performance and investor confidence.
- Notable Sales Growth: The company's sole approved drug, Imcivree, achieved sales of $194 million in 2025, reflecting a year-over-year increase of approximately 50%, highlighting the growing market demand in the rare genetic obesity treatment sector.
- Promising Clinical Trials: Rhythm expects to advance its oral MC4R agonist, bivamelagon, into Phase 3 clinical testing in 2026, alongside another candidate, RM-718, in Phase 1 testing, showcasing the diversity of its pipeline and potential for market expansion.
- FDA Approval Catalyst: The anticipated FDA approval for Imcivree in treating acquired hypothalamic obesity on March 20, 2026, could potentially benefit over 36,000 patients across the U.S., Europe, and Japan, significantly enhancing the company's market outlook and profitability prospects.
Continue Reading
Polestar Secures $400 Million Funding to Enhance Liquidity
- Funding Agreement Secured: Polestar has secured over $400 million in funding through the special purpose vehicle Feathertop Funding Ltd., with Sumitomo Mitsui Banking Corp. and Standard Chartered Bank each investing $200 million, reflecting confidence in its financial health.
- Transparent Equity Structure: Under the agreement, both banks will purchase Class A American Depositary Shares at $19.34 per share, with the option to sell their stakes within three years, ensuring neither institution will own more than 10% of Polestar's outstanding equity.
- Liquidity Enhancement: The CEO of Polestar stated that this financing will further enhance the company's liquidity position and strengthen its balance sheet, indicating positive progress in financial management.
- Market Expansion Plans: Concurrently, Geely is considering entering the U.S. market within the next 2-3 years, showcasing its ambition for global expansion, which could present new growth opportunities for Polestar.
Continue Reading